表紙
市場調査レポート

核医学/放射性医薬品の欧州市場予測 2020年:SPECT・PET・ベータ放射体・アルファ放射体・小線源療法

European Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), by Application (Oncology, Thyroid, Cardiology) - Forecasts to 2020

発行 MarketsandMarkets 商品コード 268459
出版日 ページ情報 英文 197 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
核医学/放射性医薬品の欧州市場予測 2020年:SPECT・PET・ベータ放射体・アルファ放射体・小線源療法 European Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), by Application (Oncology, Thyroid, Cardiology) - Forecasts to 2020
出版日: 2015年11月06日 ページ情報: 英文 197 Pages
概要

欧州の核医学/放射性医薬品市場は、2015年に10億9,500万米ドル規模と推計され、予測期間中は8.2%のCAGRで成長すると予測されています。SPECTおよびPETスキャンの選好の増加、放射性トレーサーの進歩、アルファ放射免疫療法を用いた癌標的療法の発明、癌・心臓病の発症率・死亡率の増加といった要因は同市場の成長を促進しています。さらに、パイプラインにおける将来性のある放射性同位体、およびサイクトロンを用いた生産は、近い将来、欧州の核医学/放射性医薬品市場へ巨大な機会を生み出す可能性があります。しかし、放射性医薬品の半減期が短いこと、また従来の診断方法との競合は、同市場の成長を抑制しています。

当レポートでは、欧州の核医学/放射性医薬品市場に注目し、主要企業が提供する製品ポートフォリオの包括的情報、種類・用途・国別の市場分析、製品開発/革新の動向、市場発展動向、競合評価、および主要企業のプロファイルなどを分析し、お届けいたします。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 欧州の核医学/放射性医薬品市場
  • SPECT核医学/放射性医薬品診断市場:国・用途別
  • 欧州の核医学/放射性医薬品市場:国別
  • 欧州の核医学/放射性医薬品市場:種類別

第5章 市場概要

  • イントロダクション
  • 市場ダイナミクス
    • 促進因子
    • 抑制因子
    • 機会
    • 緊急の課題
  • 規制状況
    • イントロダクション
    • ドイツ
    • フランス
    • 英国
    • スペイン
    • イタリア
    • ロシア
    • スイス

第6章 欧州の核医学/放射線医薬品市場:パイプライン評価

  • イントロダクション
  • 診断用放射性同位体
  • 治療用放射性同位体

第7章 欧州の核医学/放射線医薬品市場:種類別

  • イントロダクション
  • 診断用核医学/放射線医薬品
    • SPECT放射線医薬品
    • PET放射線医薬品
  • 治療用核医学/放射線医薬品
    • ベータ放射体
    • アルファ放射体
    • 小線源療法

第8章 欧州の核医学/放射線医薬品市場:用途別

  • イントロダクション
  • 診断用
    • SPECT用途
    • PET用途
  • 治療用
    • 甲状腺
    • 骨転移
    • リンパ腫
    • 内分泌腫瘍
    • その他の治療用途

第9章 欧州の核医学/放射線医薬品市場:処置数

  • イントロダクション
  • 欧州の核医学/放射線医薬品処置数:診断
    • SPECT放射線医薬品
    • PET放射線医薬品
  • 欧州の核医学/放射線医薬品処置数:治療
    • ベータ放射体
    • アルファ放射体
    • 小線源療法

第10章 欧州の核医学/放射線医薬品市場:国/地域別

  • イントロダクション
  • ドイツ
  • フランス
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他の諸国 (ROE)

第11章 競合環境

  • 概要
  • 競合状況・動向

第12章 企業プロファイル (概要、財務、製品・サービス、戦略、事業展開)

  • CARDINAL HEALTH, INC.
  • MALLINCKRODT PLC
  • GE HEALTHCARE
  • LANTHEUS MEDICAL IMAGING, INC.
  • BAYER HEALTHCARE
  • BRACCO IMAGING S.P.A
  • ECZACIBASI-MONROL NUCLEAR PRODUCTS
  • NORDION, INC.
  • ADVANCED ACCELERATOR APPLICATIONS S.A.
  • IBA MOLECULAR IMAGING

第13章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PH 1867

The European nuclear medicine/radiopharmaceuticals market is segmented on the basis of type, application, and country. The European nuclear medicine/radiopharmaceuticals market is valued at USD 1.095 billion in 2015 and is poised to grow at a CAGR of 8.2% during the forecasted period.

Factors such as increasing preference for SPECT and PET scans, advances in radiotracers, advent of alpha radio immunotherapy-based targeted cancer treatment, increasing incidence & mortality rate of cancer and cardiac ailments are driving the growth of this market. Moreover, potential radioisotopes in the pipeline, cyclotron based production are likely to create huge opportunities for this market in the coming years. However, factors such as shorter half-life of radiopharmaceuticals, competition from conventional diagnostic procedures are hindering the growth of this market.

Some of the major players in the European nuclear medicine/radiopharmaceuticals market include Cardinal Health Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt plc (Ireland).

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the European market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the European nuclear medicine/radiopharmaceuticals market. The report analyzes the European nuclear medicine/radiopharmaceuticals market by type, application, and country
  • Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the European nuclear medicine/radiopharmaceuticals market
  • Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various European nuclear medicine/radiopharmaceuticals technologies across Europe
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the European nuclear medicine/radiopharmaceuticals market
  • Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the European nuclear medicine/radiopharmaceuticals market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
    • 2.2.2. PRIMARY RESEARCH
    • 2.2.3. KEY INDUSTRY INSIGHTS
  • 2.3. KEY DATA FROM PRIMARY SOURCES
  • 2.4. KEY INSIGHTS FROM PRIMARY SOURCES
  • 2.5. MARKET SIZE ESTIMATION METHODOLOGY
  • 2.6. RESEARCH DESIGN
  • 2.7. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.8. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK

4. PREMIUM INSIGHTS

  • 4.1. EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  • 4.2. SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET, BY COUNTRY AND APPLICATION
  • 4.3. EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY COUNTRY
  • 4.4. EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE (2015 VS. 2020)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing preference for SPECT and PET scans
      • 5.2.1.2. Advances in radiotracers
      • 5.2.1.3. Alpha radioimmunotherapy-based targeted cancer treatment
      • 5.2.1.4. Growing incidence rate of cancer and cardiac ailments
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Shorter half-life of radiopharmaceuticals
      • 5.2.2.2. Competition from conventional diagnostic procedures
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Potential radioisotopes in the pipeline
      • 5.2.3.2. Cyclotron-based production
    • 5.2.4. CHALLENGE
      • 5.2.4.1. Shutdown of nuclear reactors
    • 5.2.5. BURNING ISSUE
      • 5.2.5.1. Low healthcare spending in Europe
  • 5.3. REGULATORY SCENARIO
    • 5.3.1. INTRODUCTION
    • 5.3.2. GERMANY
      • 5.3.2.1. German Medicinal Products Act (AMG)
      • 5.3.2.2. Amendments to the German Medicinal Products Act (AMG)
    • 5.3.3. FRANCE
      • 5.3.3.1. Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM)
    • 5.3.4. U.K.
      • 5.3.4.1. The Medicines and Healthcare Products Regulatory Agency (MHRA)
    • 5.3.5. SPAIN
    • 5.3.6. ITALY
      • 5.3.6.1. The Italian Pharmaceutical Agency (AIFA)
    • 5.3.7. RUSSIA
      • 5.3.7.1. The Federal Law
    • 5.3.8. SWITZERLAND
      • 5.3.8.1. Federal Department Of Home Affairs (FDHA)- The Ultimate Decision Maker
      • 5.3.8.2. The Swiss Agency For Therapeutic Products (SATP)

6. EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, PIPELINE ASSESSMENT

  • 6.1. INTRODUCTION
  • 6.2. DIAGNOSTIC RADIOISOTOPES
    • 6.2.1. F-18
  • 6.3. THERAPEUTIC RADIOISOTOPES
    • 6.3.1. RA-223
    • 6.3.2. LU-177

7. EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE

  • 7.1. INTRODUCTION
  • 7.2. DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS
    • 7.2.1. SPECT RADIOPHARMACEUTICALS
      • 7.2.1.1. Technetium-99m
      • 7.2.1.2. Thallium-201
      • 7.2.1.3. Gallium-67
      • 7.2.1.4. Iodine-123
      • 7.2.1.5. Others
    • 7.2.2. PET RADIOPHARMACEUTICALS
      • 7.2.2.1. Fluorine-18
      • 7.2.2.2. Rubidium-82
      • 7.2.2.3. Others
  • 7.3. THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS
    • 7.3.1. BETA EMITTERS
      • 7.3.1.1. Iodine-131
      • 7.3.1.2. Yttrium-90
      • 7.3.1.3. Samarium-153
      • 7.3.1.4. Rhenium-186
      • 7.3.1.5. Lutetium-177
      • 7.3.1.6. Others
    • 7.3.2. ALPHA EMITTERS
      • 7.3.2.1. Radium-223
    • 7.3.3. BRACHYTHERAPY
      • 7.3.3.1. Iodine-125
      • 7.3.3.2. Iridium-192
      • 7.3.3.3. Palladium-103
      • 7.3.3.4. Cesium-131
      • 7.3.3.5. Others

8. EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. DIAGNOSTIC APPLICATIONS
    • 8.2.1. SPECT APPLICATIONS
      • 8.2.1.1. Cardiology
      • 8.2.1.2. Lymphoma
      • 8.2.1.3. Neurology
      • 8.2.1.4. Thyroid
      • 8.2.1.5. Other SPECT Applications
    • 8.2.2. PET APPLICATIONS
      • 8.2.2.1. Oncology
      • 8.2.2.2. Cardiology
      • 8.2.2.3. Neurology
      • 8.2.2.4. Other PET Applications
  • 8.3. THERAPEUTIC APPLICATIONS
    • 8.3.1. THYROID
    • 8.3.2. BONE METASTASIS
    • 8.3.3. LYMPHOMA
    • 8.3.4. ENDOCRINE TUMORS
    • 8.3.5. OTHER THERAPEUTIC APPLICATIONS

9. EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS, PROCEDURAL VOLUME

  • 9.1. INTRODUCTION
  • 9.2. EUROPEAN DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME
    • 9.2.1. SPECT RADIOPHARMACEUTICALS
    • 9.2.2. PET RADIOPHARMACEUTICALS
  • 9.3. EUROPEAN THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME
    • 9.3.1. BETA EMITTERS
    • 9.3.2. ALPHA EMITTERS
    • 9.3.3. BRACHYTHERAPY

10. EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY COUNTRY/REGION

  • 10.1. INTRODUCTION
  • 10.2. GERMANY
  • 10.3. FRANCE
  • 10.4. ITALY
  • 10.5. U.K.
  • 10.6. SPAIN
  • 10.7. RUSSIA
  • 10.8. REST OF EUROPE (ROE)

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. COMPETITIVE SITUATION AND TRENDS
    • 11.2.1. INTRODUCTION
    • 11.2.2. AGREEMENTS & CONTRACTS
    • 11.2.3. ACQUISITIONS
    • 11.2.4. MARKET DEVELOPMENTS
    • 11.2.5. EXPANSIONS
    • 11.2.6. OTHER STRATEGIES

12. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, and Developments)*

  • 12.1. CARDINAL HEALTH, INC.
  • 12.2. MALLINCKRODT PLC
  • 12.3. GE HEALTHCARE
  • 12.4. LANTHEUS MEDICAL IMAGING, INC.
  • 12.5. BAYER HEALTHCARE
  • 12.6. BRACCO IMAGING S.P.A
  • 12.7. ECZACIBASI-MONROL NUCLEAR PRODUCTS
  • 12.8. NORDION, INC.
  • 12.9. ADVANCED ACCELERATOR APPLICATIONS S.A.
  • 12.10. IBA MOLECULAR IMAGING

*Details on overview, financials, product & services, strategy, and developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. DISCUSSION GUIDE
  • 13.2. AVAILABLE CUSTOMIZATIONS
  • 13.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.4. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: ALPHA RADIO IMMUNOTHERAPY-BASED TARGETED CANCER TREATMENT TO BOOST THE GROWTH OF THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  • TABLE 2: SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS RESTRAINING THE GROWTH OF THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  • TABLE 3: POTENTIAL RADIOISOTOPES IN THE PIPELINE OFFER SIGNIFICANT GROWTH OPPORTUNITIES FOR THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  • TABLE 4: SHUTDOWN OF NUCLEAR REACTORS IS A MAJOR CHALLENGE IN THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  • TABLE 5: LOW HEALTHCARE SPENDING IN EUROPE IS A MAJOR BURNING ISSUE IN THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  • TABLE 6: DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING DIAGNOSTIC APPLICATIONS
  • TABLE 7: DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING THERAPEUTIC APPLICATIONS
  • TABLE 8: EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 9: EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 10: EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 11: EUROPE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 12: EUROPE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2013-2020 (USD MILLION)
  • TABLE 13: EUROPE: TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 14: EUROPE: THALLIUM-201 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 15: EUROPE: GALLIUM-67 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 16: EUROPE: IODINE-123 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 17: EUROPE: OTHER SPECT ISOTOPES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 18: EUROPE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 19: EUROPE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2013-2020 (USD MILLION)
  • TABLE 20: EUROPE: FLUORINE-18 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 21: EUROPE: RUBIDIUM-82 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 22: EUROPE: OTHER PET ISOTOPES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 23: EUROPE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 24: EUROPE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 25: EUROPE: BETA EMITTERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 26: EUROPE: BETA EMITTERS MARKET SIZE, BY ISOTOPE TYPE, 2013-2020 (USD MILLION)
  • TABLE 27: EUROPE: IODINE-131 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 28: EUROPE: YTTRIUM-90 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 29: EUROPE: SAMARIUM-153 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 30: EUROPE: RHENIUM-186 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 31: EUROPE: LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 32: EUROPE: OTHER BETA EMITTER ISOTOPES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 33: EUROPE: ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 34: EUROPE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 35: EUROPE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2013-2020 (USD MILLION)
  • TABLE 36: EUROPE: IODINE-125 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 37: EUROPE: IRIDIUM-192 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 38: EUROPE: PALLADIUM-103 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 39: EUROPE: CESIUM-131 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 40: EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 41: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 42: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 43: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 44: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 45: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 46: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 47: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 48: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 49: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 50: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ONCOLOGY PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 51: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 52: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 53: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 54: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 55: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 56: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 57: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BONE METASTASIS THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 58: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 59: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ENDOCRINE THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 60: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 61: EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND)
  • TABLE 62: EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME, BY COUNTRY, 2013-2020 (THOUSAND)
  • TABLE 63: EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND)
  • TABLE 64: EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2013-2020 (THOUSAND)
  • TABLE 65: EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2013-2020 (THOUSAND)
  • TABLE 66: EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND)
  • TABLE 67: EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR BETA EMITTERS, BY TYPE, 2013-2020 (THOUSAND)
  • TABLE 68: EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR ALPHA EMITTERS, BY TYPE, 2013-2020 (THOUSAND)
  • TABLE 69: EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR BRACHYTHERAPY, BY TYPE, 2013-2020 (THOUSAND)
  • TABLE 70: EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 71: GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 72: GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 73: GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 74: GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 75: GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 76: GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 77: GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 78: GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 79: GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 80: GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 81: FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 82: FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 83: FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 84: FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 85: FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 86: FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 87: FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 88: FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 89: FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 90: FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 91: ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 92: ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 93: ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 94: ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 95: ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 96: ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 97: ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 98: ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 99: ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 100: ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 101: U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 102: U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 103: U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 104: U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 105: U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 106: U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 107: U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 108: U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 109: U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 110: U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 111: SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 112: SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 113: SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 114: SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 115: SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 116: SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 117: SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 118: SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 119: SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 120: SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 121: RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 122: RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 123: RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 124: RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 125: RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 126: RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 127: RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 128: RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 129: RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 130: RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 131: ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 132: ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 133: ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 134: ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 135: ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 136: ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 137: ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 138: ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 139: ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 140: ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 141: AGREEMENTS & CONTRACTS, 2012-2015
  • TABLE 142: ACQUISITIONS, 2012-2015
  • TABLE 143: MARKET DEVELOPMENTS, 2012-2015
  • TABLE 144: EXPANSIONS, 2012-2015
  • TABLE 145: OTHER STRATEGIES, 2012-2015

LIST OF FIGURES

  • FIGURE 1: EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICAL MARKET SEGMENTATION
  • FIGURE 2: EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 3: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 4: BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 6: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 7: RESEARCH DESIGN
  • FIGURE 8: DATA TRIANGULATION METHODOLOGY
  • FIGURE 9: THERAPEUTIC MARKET TO WITNESS HIGH GROWTH RATE FROM 2015 TO 2020
  • FIGURE 10: EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SHARE, BY TYPE, 2015 VS. 2020
  • FIGURE 11: GEOGRAPHICAL SNAPSHOT OF THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, 2015
  • FIGURE 12: EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS SPECT APPLICATIONS MARKET SIZE, 2015 VS. 2020
  • FIGURE 13: ADVANCES IN RADIOTRACERS TO PROPEL MARKET GROWTH
  • FIGURE 14: GERMANY DOMINATES THE EUROPEAN SPECT NUCLEAR MEDICINE DIAGNOSTIC MARKET IN 2015
  • FIGURE 15: REST OF EUROPE TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
  • FIGURE 16: DIAGNOSTIC SEGMENT TO COMMAND THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD
  • FIGURE 17: EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 18: CLINICAL TRIALS STUDIES OF RADIOISOTOPES, BY COUNTRY
  • FIGURE 19: CLINICAL TRIALS FOR DIAGNOSTIC & THERAPEUTIC RADIOISOTOPES, BY PHASE
  • FIGURE 20: CLINICAL TRIALS FOR DIAGNOSTIC & THERAPEUTIC RADIOISOTOPES, BY COMPANY & INSTITUTE
  • FIGURE 21: CLINICAL TRIALS FOR RADIOISOTOPES, BY TYPE
  • FIGURE 22: CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY SUBTYPE
  • FIGURE 23: CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY INDICATION
  • FIGURE 24: CLINICAL TRIALS FOR F-18, BY COUNTRY
  • FIGURE 25: CLINICAL TRIALS FOR F-18, BY PHASE
  • FIGURE 26: CLINICAL TRIALS FOR F-18, BY INDICATION
  • FIGURE 27: CLINICAL TRIALS FOR F-18, BY COMPANY/INSTITUTE
  • FIGURE 28: CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY SUBTYPE
  • FIGURE 29: CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY INDICATION
  • FIGURE 30: CLINICAL TRIALS FOR RA-223, BY COUNTRY
  • FIGURE 31: CLINICAL TRIALS FOR RA-223, BY PHASE
  • FIGURE 32: CLINICAL TRIALS FOR RA-223, BY INDICATION
  • FIGURE 33: CLINICAL TRIALS FOR RA-223, BY COMPANY/INSTITUTE
  • FIGURE 34: CLINICAL TRIALS FOR LU-177, BY COUNTRY
  • FIGURE 35: CLINICAL TRIALS FOR LU-177, BY PHASE
  • FIGURE 36: CLINICAL TRIALS FOR LU-177, BY INDICATION
  • FIGURE 37: CLINICAL TRIALS FOR LU-177, BY COMPANY/INSTITUTE
  • FIGURE 38: EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION, BY TYPE
  • FIGURE 39: THERAPEUTIC SEGMENT TO GROW AT A HIGHER CAGR OF 10.2%
  • FIGURE 40: PET SEGMENT TO GROW AT THE HIGHER CAGR OF 13.1% DURING THE FORECAST PERIOD
  • FIGURE 41: ALPHA EMITTERS SEGMENT TO GROW AT THE HIGHEST CAGR OF 12.7% DURING THE FORECAST PERIOD
  • FIGURE 42: SEGMENTATION OF EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR SPECT APPLICATIONS, BY TYPE
  • FIGURE 43: REST OF EUROPE REGION TO GROW AT THE HIGHEST CAGR OF 13.2% DURING THE FORECAST PERIOD
  • FIGURE 44: NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 8.1% DURING THE FORECAST PERIOD
  • FIGURE 45: SEGMENTATION OF EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PET APPLICATIONS, BY TYPE
  • FIGURE 46: REST OF EUROPE REGION TO GROW AT THE HIGHEST CAGR OF 20.1% DURING THE FORECAST PERIOD
  • FIGURE 47: NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 16.4% DURING THE FORECAST PERIOD
  • FIGURE 48: SEGMENTATION OF EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE
  • FIGURE 49: REST OF EUROPE REGION TO GROW AT THE HIGHEST CAGR OF 16.5% DURING THE FORECAST PERIOD
  • FIGURE 50: THE ENDOCRINE TUMORS APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 13.0% DURING THE FORECAST PERIOD
  • FIGURE 51: GERMANY TO COMMAND THE LARGEST SHARE OF THE EUROPEAN NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC IN 2015
  • FIGURE 52: THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET TO GROW AT A CAGR OF 8.2% DURING THE FORECAST PERIOD
  • FIGURE 53: BATTLE FOR MARKET SHARE: AGREEMENTS & CONTRACTS WAS THE KEY STRATEGY ADOPTED BY PLAYERS BETWEEN 2012 & 2015
  • FIGURE 54: CARDINAL HEALTH, INC.: COMPANY SNAPSHOT
  • FIGURE 55: MALLINCKRODT PLC: COMPANY SNAPSHOT
  • FIGURE 56: GE HEALTHCARE: COMPANY SNAPSHOT
  • FIGURE 57: LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT
  • FIGURE 58: BAYER HEALTHCARE: COMPANY SNAPSHOT
  • FIGURE 59: NORDION, INC.: COMPANY SNAPSHOT
  • FIGURE 60: ADVANCED ACCELERATOR APPLICATIONS S.A.: COMPANY SNAPSHOT
Back to Top